a Huntsville Hospital , Department of Pharmacy Services , Huntsville , AL , USA.
b Alabama Infectious Diseases Center , Huntsville , AL , USA.
Infect Dis (Lond). 2017 Jul;49(7):540-544. doi: 10.1080/23744235.2017.1300318. Epub 2017 Mar 15.
Infective endocarditis (IE) one-year mortality rates approach 40%. Here, we report two native valve Enterococcus faecalis IE cases in patients successfully treated with telavancin. An 88-year-old with mitral valve endocarditis and a penicillin allergy, initially treated with intravenous vancomycin, was switched to telavancin. A 69-year-old, who previously received amoxicillin and intravenous vancomycin for presumed enterococcal bacteraemia, was diagnosed with dual valve endocarditis for which he received telavancin. Both received six weeks of telavancin. Neither had telavancin-related adverse events, evidence of infection at six months, nor required telavancin dosing adjustments. Documented use of novel treatments for serious enterococcal infections is needed.
感染性心内膜炎（IE）的一年死亡率接近 40%。在这里，我们报告了两例使用替拉万星成功治疗的 native valve Enterococcus faecalis IE 病例。一名 88 岁的二尖瓣心内膜炎伴青霉素过敏患者最初接受静脉万古霉素治疗，随后改用替拉万星。一名 69 岁的患者曾因疑似肠球菌菌血症接受阿莫西林和静脉万古霉素治疗，后被诊断为双瓣心内膜炎，接受替拉万星治疗。两人均接受了六周的替拉万星治疗。两人均无替拉万星相关不良事件、六个月时无感染证据，也无需调整替拉万星剂量。需要记录新型治疗严重肠球菌感染的应用。
